Eli Lilly builds 1.5 billion dollar stockpile of weight loss pill ahead of FDA decision
Eli Lilly has built a 1.5 billion dollar stockpile of its weight loss pill ahead of an April FDA ruling. The firm seeks a smooth global launch if approved.
Insights:
Eli Lilly and Company has accumulated $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug, orforglipron, as the firm prepares for a critical regulatory milestone in the United States 
US. The buildup of stock comes ahead of an expected decision by the U.S. Food and Drug Administration in April. This significant increase in inventory, which rose from a previous level of nearly $550 million, signals the company's readiness for a potential near-simultaneous launch across multiple markets if the treatment receives regulatory clearance.
US. The buildup of stock comes ahead of an expected decision by the U.S. Food and Drug Administration in April. This significant increase in inventory, which rose from a previous level of nearly $550 million, signals the company's readiness for a potential near-simultaneous launch across multiple markets if the treatment receives regulatory clearance.
